New Delhi: Shart Tank fame Namita Thapar backed Emcure Pharmaceuticals Limited’s Rs 1,952 crore Initial Public Offer is in limelight as stock market experts have given subscribe call to the company’s stake sale process. Arun Mantri, founder, Mantri Finmart said to Money9 that investors can apply in the public issue both for listing gains and long term. Mantri said, “Overall the company is good. I think the company will do well in long term.” Moreover, Emcure Pharma IPO GMP has only shot up ever since the stake sale process hit the floors on Wednesday, July 03, 2024. Emcure Pharma IPO subscription status too was impressive on day one.
Also read: Sebi cuts debt securities’ face value to Rs 10,000
Emcure Pharma IPO GMP today
According to Investor Gain, Emcure Pharma IPO GMP today stood at Rs 330. Stock’ latest grey market premium and Emcure Pharma IPO price band of Rs 960 to Rs 1,008, signify Emcure Pharma IPO listing gains of around 33 per cent. Albeit, GMP cannot be considered as an official number.
Emcure Pharma IPO Subscription Status
Emcure Pharma IPO Subscription Status was 1.34 times the total issue size on day two. While, Emcure Pharma IPO retail quota was subscribed 1.46 times its allotted size. And, Non-Institutional Investors'(NIIs) quota was subscribed 2.78 times.
Emcure Pharma IPO Allotment Date
Emcure Pharma IPO expected allotment date is Monday, July 8, 2024. While, IPO allottees can expect credit of shares in demat account from the following date. While, refund process of non-IPO allottees would also commence from Tuesday.
Expected Emcure Pharma IPO Listing Date
Emcure Pharma IPO shares are expected to be listed on the NSE and BSE on Wednesday, July 10, 2024. IPO proceeds will be used towards payment of debt and for general corporate purposes.
Also read: Vraj Iron and Steel IPO expert review
Emcure Pharma IPO Details
Emcure Pharma IPO retail investors’ minimum investment amount is Rs 13,440. Retail investors can bid for a minimum of 14 shares in a single lot and in multiples thereof.
Namita Thapar Company
Entrpreneur Namita Thapar has been long term investor in API manufacturer, Emcure Pharmaceuticals Limited. She currently owns 3.5 per cent stake in the pharma company. She would trim her stake in the company in the public issue via Offer For Sale (OFS).
(Disclaimer: This article is only meant to provide information. News9live.com does not recommend buying or selling shares or subscriptions of any IPO and Mutual Funds.)
Arun Mantri, founder, Mantri Finmart gives subscribe call to Emcure Pharma IPO. Mantri said, “Investors can apply in the public issue both for listing gains and long term.” Markets Business News – Personal Finance News, Share Market News, BSE/NSE News, Stock Exchange News Today
